ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
After synthesizing this indenothiazepinone derivative, Mohamed A. Seleem noticed the branching, tree-like design it made on the walls of this vial. Seleem is a PhD student in the lab of Martin Conda-Sheridan at the University of Nebraska Medical Center studying the antimicrobial activity of this group of compounds against microorganisms like the ones that cause malaria and chlamydia. The structure of the protein that these researchers think they are targeting, ClpX, still has not been solved, so they are modifying the indenothiazepinone molecules and testing their activity against ClpX to see if they can tease out how the protein works and how it’s structured.
Submitted by Mohamed A. Seleem
Do science. Take pictures. Win money. Enter our photo contest here.
Related C&EN Content:
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X